RESUMEN
In the last few years, the importance of neoantigens in the development of personalized antitumor vaccines has increased remarkably. In order to study whether bioinformatic tools are effective in detecting neoantigens that generate an immune response, DNA samples from patients with cutaneous melanoma in different stages were obtained, resulting in a total of 6048 potential neoantigens gathered. Thereafter, the immunological responses generated by some of those neoantigens ex vivo were tested, using a vaccine designed by a new optimization approach and encapsulated in nanoparticles. Our bioinformatic analysis indicated that no differences were found between the number of neoantigens and that of non-mutated sequences detected as potential binders by IEDB tools. However, those tools were able to highlight neoantigens over non-mutated peptides in HLA-II recognition (p-value 0.03). However, neither HLA-I binding affinity (p-value 0.08) nor Class I immunogenicity values (p-value 0.96) indicated significant differences for the latter parameters. Subsequently, the new vaccine, using aggregative functions and combinatorial optimization, was designed. The six best neoantigens were selected and formulated into two nanoparticles, with which the immune response ex vivo was evaluated, demonstrating a specific activation of the immune response. This study reinforces the use of bioinformatic tools in vaccine development, as their usefulness is proven both in silico and ex vivo.
Asunto(s)
Vacunas contra el Cáncer , Melanoma , Neoplasias , Neoplasias Cutáneas , Humanos , Antígenos de Neoplasias/genética , Inmunidad , Desarrollo de Vacunas , Neoplasias/genéticaRESUMEN
Vaccination using proteins and peptides is currently gaining importance. One of the major drawbacks of this approach is the lack of an efficient immune response when the antigens are administered without adjuvants. In this study, we have taken the advantage of a combined adjuvant system in order to improve the immunogenicity of the SPf66 malarial antigen. For that purpose, we have combined poly (lactic-co-glycolic) acid microspheres, alginate, and polyinosinic polycytidilic acid. Our results show that microspheres can enhance the IgG production obtained with Freund's complete adjuvant. We have attributed this improvement to the presence of polyinosinic polycytidilic acid, since formulations comprising this adjuvant overcame the immune response from the others. In addition, our microspheres produced both IgG1 and IgG2a, leading to mixed Th1/Th2 activation, optimal for malaria vaccination. In conclusion, we have designed a preliminary formulation with a high potential for the treatment of malaria.
Asunto(s)
Alginatos , Inductores de Interferón , Ácido Láctico , Vacunas contra la Malaria , Microesferas , Poli I-C , Ácido Poliglicólico , Alginatos/química , Alginatos/farmacología , Animales , Anticuerpos Antiprotozoarios/sangre , Anticuerpos Antiprotozoarios/inmunología , Femenino , Ácido Glucurónico/química , Ácido Glucurónico/farmacología , Ácidos Hexurónicos/química , Ácidos Hexurónicos/farmacología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inductores de Interferón/química , Inductores de Interferón/farmacología , Ácido Láctico/química , Ácido Láctico/farmacología , Malaria/sangre , Malaria/inmunología , Malaria/prevención & control , Vacunas contra la Malaria/química , Vacunas contra la Malaria/farmacología , Ratones , Ratones Endogámicos BALB C , Poli I-C/química , Poli I-C/farmacología , Ácido Poliglicólico/química , Ácido Poliglicólico/farmacología , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Células TH1/inmunología , Células TH1/microbiología , Células Th2/inmunología , Células Th2/metabolismoRESUMEN
Negatively charged microspheres (NCMs) represent a new therapeutic approach for wound healing since recent clinical trials have shown NCM efficacy in the recovery of hard-to-heal wounds that tend to stay in the inflammatory phase, unlocking the healing process. The aim of this study was to elucidate the NCM mechanism of action. NCMs were extracted from a commercial microsphere formulation (PolyHeal® Micro) and cytotoxicity, attachment, proliferation and viability assays were performed in keratinocytes and dermal fibroblasts, while macrophages were used for the phagocytosis and polarization assays. We demonstrated that cells tend to attach to the microsphere surface, and that NCMs are biocompatible and promote cell proliferation at specific concentrations (50 and 10 NCM/cell) by a minimum of 3 fold compared to the control group. Furthermore, NCM internalization by macrophages seemed to drive these cells to a noninflammatory condition, as demonstrated by the over-expression of CD206 and the under-expression of CD64, M2 and M1 markers, respectively. NCMs are an effective approach for reverting the chronic inflammatory state of stagnant wounds (such as diabetic wounds) and thus for improving wound healing.
RESUMEN
Designing strategies for targeting antigens to dendritic cells is a major goal in vaccinology. Here, PLGA (poly lactic-co-glycolic acid) microspheres and with several surface modifications that affect to their uptake by human blood primary dendritic cells and monocytes have been evaluated. Higher uptake was found by all the cell types when cationic microspheres (PLGA modified with polyethylene imine) were used. These cationic particles were in vivo evaluated in mice. In addition, MPLA(1) or poly(I:C)(2) and α-GalCer(3) were also encapsulated to address their adjuvant effect. All the microspheres were able to produce humoral immune responses, albeit they were higher for cationic microspheres. Moreover, surface charge seemed to have a role on biasing the immune response; cationic microspheres induced higher IFN-γ levels, indicative of Th1 activation, while unmodified ones mainly triggered IL4 and IL17A release, showing Th2 activation. Thus, we have shown here the potential and versatility of these MS, which may be tailored to needs.
Asunto(s)
Adyuvantes Inmunológicos/metabolismo , Células Dendríticas/metabolismo , Diseño de Fármacos , Ácido Láctico/metabolismo , Microesferas , Ácido Poliglicólico/metabolismo , Vacunas/metabolismo , Adyuvantes Inmunológicos/síntesis química , Animales , Células Cultivadas , Evaluación Preclínica de Medicamentos/métodos , Femenino , Humanos , Ácido Láctico/síntesis química , Ratones , Ratones Endogámicos BALB C , Ácido Poliglicólico/síntesis química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Propiedades de Superficie , Resultado del Tratamiento , Vacunas/síntesis químicaRESUMEN
There is no malaria vaccine currently available, and the most advanced candidate has recently reported a modest 30% efficacy against clinical malaria. Although many efforts have been dedicated to achieve this goal, the research was mainly directed to identify antigenic targets. Nevertheless, the latest progresses on understanding how immune system works and the data recovered from vaccination studies have conferred to the vaccine formulation its deserved relevance. Additionally to the antigen nature, the manner in which it is presented (delivery adjuvants) as well as the immunostimulatory effect of the formulation components (immunostimulants) modulates the immune response elicited. Protective immunity against malaria requires the induction of humoral, antibody-dependent cellular inhibition (ADCI) and effector and memory cell responses. This review summarizes the status of adjuvants that have been or are being employed in the malaria vaccine development, focusing on the pharmaceutical and immunological aspects, as well as on their immunization outcomings at clinical and preclinical stages.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Vacunas contra la Malaria/administración & dosificación , Malaria/prevención & control , Proteínas Protozoarias/inmunología , Antígenos de Protozoos/inmunología , Investigación Biomédica , Humanos , Malaria/inmunología , Malaria/parasitología , Plasmodium falciparum/inmunología , Plasmodium falciparum/patogenicidadRESUMEN
Currently, a vaccine against malaria has not yet been licensed. Different approaches have been explored with different immune responses, but neither has fulfilled the criteria for being approved. The most advanced candidate, RTS,S, is undergoing Phase III studies and comprises virus-like particles, liposomes and immunostimulatory molecules. Other strategies are based on the use of polymeric particles, viral vectors or virosomes. Here, the authors have summarized the clinical advances that have been made in the field of Plasmodium falciparum to date, since it is the main causal agent of severe malaria. The best strategies to further develop a vaccine against malaria have also been discussed. In fact, an appropriate formulation should be immunogenic, safe and well tolerated, and as far as possible, avoid the use of needles and require a low number of immunizations. Moreover, issues such as storage, costs and so on, have to be taken into account.
Asunto(s)
Vacunas contra la Malaria/inmunología , Malaria Falciparum/prevención & control , Plasmodium falciparum/inmunología , Ensayos Clínicos como Asunto , Descubrimiento de Drogas/tendencias , Humanos , Vacunas contra la Malaria/químicaRESUMEN
The development of vaccines that generate mixed humoral and cellular immune responses is a challenge in vaccinology. Poly(lactide-co-glycolide) microspheres are vaccine adjuvants which possess the advantage of allowing the coencapsulation of other adjuvants in addition to the antigen. Thus, we can stimulate the immune system from different ways and resemble the effects of a natural infection. In this study, we have coencapsulated BSA with monophosphoryl lipid A, polyinosinic-polycytidylic acid, α-galactosylceramide and alginate into PLGA microspheres. All the microspheres have developed a higher humoral immune response, in terms of release of total IgG, in comparison to the administration of soluble antigen. In addition, they triggered a more balanced IgG1/IgG2a response. The combination of MPLA and α-galactosylceramide within the microspheres developed the higher cellular response, confirming that combination of adjuvants with different action mechanisms is a good strategy to increase vaccines' immunogenicity.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Portadores de Fármacos/administración & dosificación , Microesferas , Poliglactina 910/administración & dosificación , Albúmina Sérica Bovina/inmunología , Vacunas/inmunología , Animales , Anticuerpos/sangre , Femenino , Inmunoglobulina G/sangre , Ratones , Ratones Endogámicos BALB C , Albúmina Sérica Bovina/administración & dosificación , Vacunas/administración & dosificaciónRESUMEN
The development of synthetic peptide-based vaccines has many advantages in comparison with vaccines based on live attenuated organisms, inactivated or killed organism, or toxins. Peptide-based vaccines cannot revert to a virulent form, allow a better conservation, and are produced more easily and safely. However, they generate a weaker immune response than other vaccines, and the inclusion of adjuvants and/or the use of vaccine delivery systems is almost always needed. Among vaccine delivery systems, micro- and nanoparticulated ones are attractive, because their particulate nature can increase cross-presentation of the peptide. In addition, they can be passively or actively targeted to antigen presenting cells. Furthermore, particulate adjuvants are able to directly activate innate immune system in vivo. Here, we summarize micro- and nanoparticulated vaccine delivery systems used in the field of synthetic peptide-based vaccines as well as strategies to increase their immunogenicity.